Inventiva S.A. American Depository Shares (IVA) Stock Price

IVAStock
$2.94−12.76%52W
Market Cap$694.49M
P/E—
PEG Ratio—
Div yield—
Beta-0.45

IVA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-53.16%
Price vs S&P 500 (4W)-11.57%
VGM Score30.25

IVA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.44
4.44
4.41
4.41

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
IVAInventiva S.A. American Depository Shares
FDC150.5x-51.3%——$2.94
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Inventiva S.A. American Depository Shares

Inventiva SA is a French biopharmaceutical company developing drug candidates targeting nuclear receptors and epigenetic pathways. Its lead program, lanifibranor, is being advanced for non-alcoholic steatohepatitis (NASH), a disease with no currently approved treatments, representing a significant commercial opportunity. The company maintains a pre-clinical pipeline in oncology, fibrosis, and rare diseases, and generates revenue through research partnerships with major pharmaceutical partners including AbbVie and BI.